Joy Yan
Chief Tech/Sci/R&D Officer chez KEYMED BIOSCIENCES INC.
Fortune : - $ au 31/03/2024
Profil
Joy Yan currently works at Moleculin Biotech, Inc., as Independent Director from 2022 and Keymed Biosciences, Inc., as Chief Medical Officer from 2022.
Dr. Yan also formerly worked at Bayer AG, as Director-Clinical Development, Checkmate Pharmaceuticals, Inc., as Director from 2021 to 2022, Ambrx, Inc., as Chief Medical Officer, and Ambrx Biopharma Cayman, Inc., as Chief Medical Officer.
Dr. Yan received her doctorate degree from The Johns Hopkins University and doctorate degree from China Medical University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MOLECULIN BIOTECH, INC.
-.--% | 26/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Joy Yan
| Sociétés | Poste | Début |
|---|---|---|
| MOLECULIN BIOTECH, INC. | Director/Board Member | 01/03/2022 |
| KEYMED BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01/01/2022 |
Anciens postes connus de Joy Yan
| Sociétés | Poste | Fin |
|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31/05/2022 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | - |
| BAYER AG | Corporate Officer/Principal | - |
| AMBRX INC | Chief Tech/Sci/R&D Officer | - |
Formation de Joy Yan
| The Johns Hopkins University | Doctorate Degree |
| China Medical University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BAYER AG | Health Technology |
| MOLECULIN BIOTECH, INC. | Health Technology |
| KEYMED BIOSCIENCES INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
